NEW YORK, February 16, 2017 /PRNewswire/ --
This morning, Stock-Callers.com has issued research reports on selectMedical Laboratories and Research equities, namely: Thermo Fisher Scientific Inc. (NYSE: TMO), VWR Corp. (NASDAQ: VWR), Laboratory Corp. of America Holdings (NYSE: LH), and Bruker Corp. (NASDAQ: BRKR). These companies are part of the Healthcare sector,
Thermo Fisher Scientific
Shares in Massachusetts headquartered Thermo Fisher Scientific Inc. rose 0.62%, ending Wednesday's trading session at $158.26. The stock recorded a trading volume of 1.42 million shares. The Company's shares have gained 9.11% in the last one month, 7.03% over the previous three months, and 12.16% on an YTD basis. The stock is trading 8.54% and 5.66% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Thermo Fisher Scientific, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide, have a Relative Strength Index (RSI) of 75.72.
On January 18th, 2017, research firm Deutsche Bank initiated a 'Buy' rating on the Company's stock, with a target price of $163 per share.
On February 14th, 2017, Thermo Fisher announced that it has completed its previously announced acquisition of Finesse Solutions, Inc., a leader in the development of scalable control automation systems and software for bioproduction. The business will be integrated into Thermo Fisher's Life Sciences Solutions Segment. Terms of the transaction were not disclosed. TMO complete research report is just a click away and free at:
Pennsylvania-based VWR Corp.'s stock climbed 0.72%, closing the day at $26.43. A total volume of 1.28 million shares was traded, which was above their three months average volume of 867,840 shares. The Company's shares have advanced 5.38% in the past month, 0.61% over the previous three months, and 5.59% since the start of this year. The stock is trading 3.49% above its 50-day moving average. Additionally, shares of VWR, which together with its subsidiaries, operates as an independent provider of laboratory products, services, and solutions to the life science, general research, and applied markets, have an RSI of 59.54.
On January 18th, 2017, research firm Deutsche Bank downgraded the Company's stock rating from 'Buy' to 'Hold', with a target price of $26 per share.
On February 02nd, 2017, VWR announced that it will release its Q4 and full year 2016 financial results on February 24, 2017, before the market opens. An investor conference call and live webcast will be hosted by the VWR's management team on the same day at 8:00 AM ET. The complimentary report on VWR can be downloaded at:
Laboratory Corp. of America
On Wednesday, shares in North Carolina headquartered Laboratory Corp. of America Holdings recorded a trading volume of 1.01 million shares, which was above their three months average volume of 728,700 shares. The stock ended the day 0.36% higher at $136.37. The Company's shares have gained 1.78% in the last month, 6.96% in the previous three months, and 6.22% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.18% and 3.29%, respectively. Furthermore, shares of Laboratory Corp. of America, which operates as an independent clinical laboratory company worldwide, have an RSI of 59.83.
On January 10th, 2017, the Company announced that it will acquire assets of Mount Sinai's Health System, one of the largest health systems in metropolitan New York City. When the transaction is complete, LabCorp will be available to provide comprehensive laboratory services to physicians and patients that currently use Mount Sinai's outreach laboratory.
On February 06th, 2017, research firm Robert W. Baird downgraded the Company's stock rating from 'Outperform' to 'Neutral', with a target price of $138 per share. Sign up for your complimentary research report on LH at:
Massachusetts headquartered Bruker Corp.'s stock dropped 1.92%, finishing yesterday's session at $24.06. A total volume of 1.76 million shares was traded, which was above their three months average volume of 714,290 shares. The Company's shares have advanced 6.08% in the last one month, 6.70% in the previous three months, and 13.60% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.39% and 3.87%, respectively. Additionally, shares of Bruker, which together with its subsidiaries, designs and manufactures scientific instruments, and analytical and diagnostic solutions worldwide, have an RSI of 56.68.
On January 18th, 2017, research firm Deutsche Bank initiated a 'Hold' rating on the Company's stock, with a target price of $24 per share. Get free access to your research report on BRKR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...
Drug abuse is a negative social trend that pushes youth to drug addiction in the pretext of getting ...
Proper understanding of waste collection, segregation and management is required to reduce the ...View All